A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants With Type 1 Diabetes

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carmot Therapeutics, Inc.
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Female or male adults with Type 1 diabetes

• Ages 18-65 years

• Type 1 DM for at least 3 years

• Using an insulin pump for at least 3 months

• BMI 25.0 - 35.0

Exclusion Criteria:

• Significant medical history

• Uncontrolled diabetes

• History of surgical treatment for weight loss

• History of malignancy